These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16536504)

  • 1. An alpha-helical peptidomimetic inhibitor of the HIV-1 Rev-RRE interaction.
    Mills NL; Daugherty MD; Frankel AD; Guy RK
    J Am Chem Soc; 2006 Mar; 128(11):3496-7. PubMed ID: 16536504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of HIV-1 Rev-RRE interaction by diphenylfuran derivatives.
    Ratmeyer L; Zapp ML; Green MR; Vinayak R; Kumar A; Boykin DW; Wilson WD
    Biochemistry; 1996 Oct; 35(42):13689-96. PubMed ID: 8885849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of HIV Rev peptides with the Rev response element RNA.
    Williamson JR; Battiste JL; Mao H; Frankel AD
    Nucleic Acids Symp Ser; 1995; (33):46-8. PubMed ID: 8643394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proflavine acts as a Rev inhibitor by targeting the high-affinity Rev binding site of the Rev responsive element of HIV-1.
    DeJong ES; Chang CE; Gilson MK; Marino JP
    Biochemistry; 2003 Jul; 42(26):8035-46. PubMed ID: 12834355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of neomycin and Rev peptide binding to the Rev responsive element of HIV-1 as determined by fluorescence and NMR spectroscopy.
    Lacourciere KA; Stivers JT; Marino JP
    Biochemistry; 2000 May; 39(19):5630-41. PubMed ID: 10801313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The amino terminal domain of HIV-1 Rev is required for discrimination of the RRE from nonspecific RNA.
    Daly TJ; Doten RC; Rusche JR; Auer M
    J Mol Biol; 1995 Oct; 253(2):243-58. PubMed ID: 7563086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence specificity in the higher-order interaction of the Rev protein of HIV-1 with its target sequence, the RRE.
    Powell DM; Zhang MJ; Konings DA; Wingfield PT; Stahl SJ; Dayton ET; Dayton AI
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):317-23. PubMed ID: 7552493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exchange of the basic domain of human immunodeficiency virus type 1 Rev for a polyarginine stretch expands the RNA binding specificity, and a minimal arginine cluster is required for optimal RRE RNA binding affinity, nuclear accumulation, and trans-activation.
    Nam YS; Petrovic A; Jeong KS; Venkatesan S
    J Virol; 2001 Mar; 75(6):2957-71. PubMed ID: 11222721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arginine side-chain dynamics in the HIV-1 rev-RRE complex.
    Wilkinson TA; Botuyan MV; Kaplan BE; Rossi JJ; Chen Y
    J Mol Biol; 2000 Nov; 303(4):515-29. PubMed ID: 11054288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of HIV Rev peptides containing peptide nucleic acid that bind HIV RRE IIB RNA.
    Kumagai I; Takahashi T; Hamasaki K; Ueno A; Mihara H
    Bioorg Med Chem Lett; 2000 Feb; 10(4):377-9. PubMed ID: 10714504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costabilization of peptide and RNA structure in an HIV Rev peptide-RRE complex.
    Tan R; Frankel AD
    Biochemistry; 1994 Dec; 33(48):14579-85. PubMed ID: 7981219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide-triggered conformational switch in HIV-1 RRE RNA complexes.
    Gosser Y; Hermann T; Majumdar A; Hu W; Frederick R; Jiang F; Xu W; Patel DJ
    Nat Struct Biol; 2001 Feb; 8(2):146-50. PubMed ID: 11175904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of the Rev-RRE interaction by aromatic heterocyclic compounds.
    Zapp ML; Young DW; Kumar A; Singh R; Boykin DW; Wilson WD; Green MR
    Bioorg Med Chem; 1997 Jun; 5(6):1149-55. PubMed ID: 9222509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of the human immunodeficiency virus type 1 Rev protein with a structured region in env mRNA is dependent on multimer formation mediated through a basic stretch of amino acids.
    Olsen HS; Cochrane AW; Dillon PJ; Nalin CM; Rosen CA
    Genes Dev; 1990 Aug; 4(8):1357-64. PubMed ID: 2227413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural change in Rev responsive element RNA of HIV-1 on binding Rev peptide.
    Peterson RD; Feigon J
    J Mol Biol; 1996 Dec; 264(5):863-77. PubMed ID: 9000617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dynamic in vivo view of the HIV-I Rev-RRE interaction.
    Charpentier B; Stutz F; Rosbash M
    J Mol Biol; 1997 Mar; 266(5):950-62. PubMed ID: 9086273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereospecificity of short Rev-derived peptide interactions with RRE IIB RNA.
    Litovchick A; Rando RR
    RNA; 2003 Aug; 9(8):937-48. PubMed ID: 12869705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational analysis of the HIV-1 Rev protein and its target sequence, the Rev responsive element.
    Olsen HS; Beidas S; Dillon P; Rosen CA; Cochrane AW
    J Acquir Immune Defic Syndr (1988); 1991; 4(6):558-67. PubMed ID: 2023097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric inhibition of the HIV-1 Rev/RRE interaction by a 3'-methylphosphonate modified antisense oligo-2'-O-methylribonucleotide.
    Prater CE; Saleh AD; Wear MP; Miller PS
    Oligonucleotides; 2007; 17(3):275-90. PubMed ID: 17854268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA-ligand interactions: affinity and specificity of aminoglycoside dimers and acridine conjugates to the HIV-1 Rev response element.
    Luedtke NW; Liu Q; Tor Y
    Biochemistry; 2003 Oct; 42(39):11391-403. PubMed ID: 14516190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.